Patrick Durisch
@dbdurisch.bsky.social
Health Policy - Politique Santé Public Eye (formerly the Berne Declaration)
www.publiceye.ch
www.publiceye.ch
Both #Roche and #Novartis reported a net income of around US$ 14 billion in 2025 - so absolutely no need to cry wolf and threaten access to new drugs in 🇪🇺 🇨🇭.
Especially since Trump's moves are so far very much harmless for #BigPharma, as expressed in my recent blog www.publiceye.ch/fr/regard/de...
Especially since Trump's moves are so far very much harmless for #BigPharma, as expressed in my recent blog www.publiceye.ch/fr/regard/de...
Deals des pharmas suisses aux États-Unis: une farce au goût amer
Peu avant Noël, les géants bâlois Roche et Novartis ont conclu un « deal » très attendu avec la Maison blanche sur le prix des médicaments aux États-Unis. Contrairement à ce qu’on pourrait croire, le ...
www.publiceye.ch
February 4, 2026 at 3:28 PM
Both #Roche and #Novartis reported a net income of around US$ 14 billion in 2025 - so absolutely no need to cry wolf and threaten access to new drugs in 🇪🇺 🇨🇭.
Especially since Trump's moves are so far very much harmless for #BigPharma, as expressed in my recent blog www.publiceye.ch/fr/regard/de...
Especially since Trump's moves are so far very much harmless for #BigPharma, as expressed in my recent blog www.publiceye.ch/fr/regard/de...
Hier noch eine Einordnung des erwähnten Deals mit #Roche & Co in den USA www.publiceye.ch/de/standpunk...
US-Deal der Schweizer Pharma: eine bittere Farce
Ende letzten Jahres kam es zum mit Spannung erwarteten «Deal» von Roche und Novartis mit dem Weissen Haus über Medikamentenpreise in den USA. Für Patient*innen dies- und jenseits des Atlantiks ist die...
www.publiceye.ch
January 29, 2026 at 4:58 PM
Hier noch eine Einordnung des erwähnten Deals mit #Roche & Co in den USA www.publiceye.ch/de/standpunk...
@publiceye.ch extensively reported about Roche's patent evergreening strategy on its breast cancer treatments trastuzumab & follow-on products. This led to complaints by competition authorities a.o. in South Africa. When will 🇨🇭start to act? www.publiceye.ch/en/topics/ph...
Abusive pharma patents: Roche’s “mAb” empire
An exclusive tally of Roche’s patent portfolio for its four monoclonal antibodies (“mAb”) treatments for breast cancer shows that, 27 years after the first product hit the market, about 100 patents st...
www.publiceye.ch
December 11, 2025 at 8:22 AM
@publiceye.ch extensively reported about Roche's patent evergreening strategy on its breast cancer treatments trastuzumab & follow-on products. This led to complaints by competition authorities a.o. in South Africa. When will 🇨🇭start to act? www.publiceye.ch/en/topics/ph...